Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an european referral centre real-life experience

HIGHLIGHTS

SUMMARY

PEG monotherapy has been proven to normalize IGF-I levels in about 90% of patients in clinical trials and near to 70% of patients in real- world studies. Recent studies have demonstrated that long-term (i.e. up to 10 years) PEG therapy improves disease control over time, both in monotherapy and in combination with SRLs. Concerning long-term PEG efficacy, the analysis of data deriving from ACROSTUDY, a global non-interventional surveillance study of long-term treatment with PEG, agree with the results of other previous studies on smaller populations. According to a . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.